ReviewEnvironmental health perspectives2000
Interstitial fibrosis and growth factors.
Review in Environmental health perspectives, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 127 citations in OpenAlex.
- Involvement of pulmonary endothelial cell injury in the pathogenesis of pulmonary fibrosis: clinical assessment by 123I-MIBG lung scintigraphy.European journal of nuclear medicine and molecular imaging · 2005Trial
- Maximizing the Therapeutic Effect of Endothelin Receptor Antagonists in Pulmonary Fibrosis: A Paradigm for Treating the Disease.International journal of molecular sciences · 2024Article
- Regulatory Cues in Pulmonary Fibrosis-With Emphasis on the AIM2 Inflammasome.International journal of molecular sciences · 2023Review
- Plumbagin attenuates Bleomycin-induced lung fibrosis in mice.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2022Article
- Acanthosis nigricans in the setting of severe pulmonary disease exacerbated by COVID-19 infection.JAAD case reports · 2022Article
- Nintedanib-Containing Dual Conjugates Targeting αACS omega · 2022Article
- Efficacy of Water-Soluble Pearl Powder Components Extracted by a COMaterials (Basel, Switzerland) · 2021Article
- Proteomic analysis of serum samples of paracoccidioidomycosis patients with severe pulmonary sequel.PLoS neglected tropical diseases · 2021Article
- Air Pollution-An Overlooked Risk Factor for Idiopathic Pulmonary Fibrosis.Journal of clinical medicine · 2020Review
- Exosomes: From Potential Culprits to New Therapeutic Promise in the Setting of Cardiac Fibrosis.Cells · 2020Review
- Gastric Acid and Pepsin Work Together in Simulated Gastric Acid Inhalation Leading to Pulmonary Fibrosis in Rats.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Article
- Article
- Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models.Pharmaceutical biology · 2017Article
- Myofibroblast repair mechanisms post-inflammatory response: a fibrotic perspective.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2017Review
- Haploinsufficiency of the folliculin gene leads to impaired functions of lung fibroblasts in patients with Birt-Hogg-Dubé syndrome.Physiological reports · 2016Article
- miR-877-3p targets Smad7 and is associated with myofibroblast differentiation and bleomycin-induced lung fibrosis.Scientific reports · 2016Article
- Expression of WNT5A in Idiopathic Pulmonary Fibrosis and Its Control by TGF-β and WNT7B in Human Lung Fibroblasts.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2016Article
- Role of caveolae in high glucose and TGF-β₁ induced fibronectin production in rat mesangial cells.International journal of clinical and experimental pathology · 2014Article
- Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis.Current opinion in pharmacology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Interstitial pulmonary fibrosis (IPF) is scarring of the lung caused by a variety of inhaled agents including mineral particles, organic dusts, and oxidant gases. The disease afflicts millions of individuals worldwide, and there are no effective therapeutic approaches. A major reason for this lack of useful treatments is that few of the molecular mechanisms of disease have been defined sufficiently to design appropriate targets for therapy. Our laboratory has focused on the molecular mechanisms through which three selected peptide growth factors could play a role in the development of IPF. Hundreds of growth factors and cytokines could be involved in the complex disease process. We are studying platelet-derived growth factor because it is the most potent mesenchymal cell mitogen yet described, transforming growth factor beta because it is a powerful inducer of extracellular matrix (scar tissue) components by mesenchymal cells, and tumor necrosis factor alpha because it is a pleiotropic cytokine that we and others have shown is essential for the development of IPF in animal models. This review describes some of the evidence from studies in humans, in animal models, and in vitro, that supports the growth factor hypothesis. The use of modern molecular and transgenic technologies could elucidate those targets that will allow effective therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.